文献速递免疫规划

COVID-19疫苗接种后急性反应的发生频率及风险人群

How frequent are acute reactions to COVID-19 vaccination and who is at risk?
PubMed 文献 · Vaccine · 2022-02-09

该研究通过2021年3月19日至7月15日期间纳入的6966名完成COVID-19疫苗接种的志愿者,描述了辉瑞、莫德纳和强生疫苗接种后自我报告的短期副作用。仅3.1%因接种后副作用就医,住院和严重过敏反应罕见;92.4%报告至少一种副作用,第二剂后副作用更多。自身免疫疾病或肺病患者就医可能性约翻倍,而糖尿病和流感疫苗接种者报告3种及以上症状的可能性较低。

要点

  • 完成疫苗接种的6966名志愿者中,仅3.1%因接种后副作用就医,住院(0.3%)和严重过敏反应(0.6%)罕见。
  • 92.4%报告至少一种副作用,注射部位反应(78.9%)、疲劳(70.3%)、头痛(49.0%)最常见。
  • 两剂疫苗第二剂后副作用数量多于第一剂,强生单剂疫苗副作用中位数为3。

核心结论

  • 两剂疫苗的总副作用负担较高,但三种疫苗均相对安全;极少数受试者报告需就医的严重副作用或接种后住院。
  • 这些发现未涉及长期效应,但提供了短期安全性和耐受性信息,有望为三种疫苗的获益-风险和药物经济学评估提供参考。

研究设计与样本

  • 基于网络的注册研究,纳入2021年3月19日至7月15日期间接种COVID-19疫苗的志愿者,收集完成疫苗接种方案(辉瑞、莫德纳、强生)后的自我报告短期副作用、就医、住院和生活质量影响。
  • 共招募6966名完成全程疫苗接种的志愿者(中位年龄48岁,IQR 35.0-62.0;83.6%为女性):辉瑞3486人;莫德纳2857人;强生623人。

主要发现

  • 3.1%的参与者因接种后副作用就医;住院17例(0.3%),严重过敏反应39例(0.6%)。
  • 92.4%的参与者报告至少1种副作用(中位数3种),最常见为注射部位反应(78.9%)、疲劳(70.3%)、头痛(49.0%)。
  • 两剂疫苗第二剂后报告的副作用数量多于第一剂(辉瑞第一剂与第二剂中位数分别为1和2;莫德纳分别为1和3),强生单剂疫苗中位数为3。
  • 在职参与者因病缺勤中位数为1天;糖尿病患者报告3种及以上症状的aOR为0.68(95% CI: 0.56; 0.82),流感疫苗接种者aOR为0.82(95% CI: 0.73; 0.93)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Our objective was to describe and compare self-reported side effects ofCOVID-19 vaccinesin theUSA. METHODS: Aweb-basedregistry enrolled volunteers who received a COVID-19 vaccine between March 19-July 15, 2021. We collected self-reported short-term side effects, medical consultation, hospitalization, and quality of life impact following completed vaccination regimens (Pfizer, Moderna, J&J). RESULTS: We recruited 6,966 volunteers who completed their full course of vaccination (median age 48 years, IQR 35.0-62.0; 83.6% female): Pfizer 3,486; Moderna 2,857; J&J 623. Few (3.1%) sought medical care for post-vaccination side effects. Hospitalization (n = 17; 0.3%) and severe allergic reactions (n = 39; 0.6%) also were rare. Those with autoimmune disease or lung disease were approximately twice as likely to seek medical care (adjusted odds ratio (aOR) 2.01, 95% CI:1.39; 2.92 and aOR 1.70, 95% CI: 1.12; .58 respectively). 92.4% of participantsreported ≥ 1side effect (median 3), with injection site reactions (78.9%), fatigue (70.3%), headache (49.0%) reported most frequently. More side effects were reported after the second dose of two-dose vaccines (medians: 1 vs. 2 for Pfizer and 1 vs. 3 for Moderna for first and second doses respectively) versus 3 for J&J's single-dose vaccine. For the employed, the median number of workdays missed was one. Diabetics and those vaccinated against influenza were substantially less likely to report 3 or more symptoms (aOR 0.68, 95% CI: 0.56;0.82] and aOR 0.82, 95% CI: 0.73;0.93, respectively). DISCUSSION: The total side effect burden was, not unexpectedly, greater with two-dose regimens but all three vaccines appear relatively safe. Very few subjects reported side effects serious enough to warrant medical care or reported post-vaccination hospitalization. While these findings do not address possible long-term effects, they do inform on their short-term safety and tolerability and will hopefully provide some reassurance and positively inform the benefit-risk and pharmacoeconomic assessment for all three vaccines. See Clinicaltrials.gov NCT04368065.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dreyer N, Reynolds MW, Albert L, et al. How frequent are acute reactions to COVID-19 vaccination and who is at risk? Vaccine. 2022. PMID: 35177299. doi:10.1016/j.vaccine.2021.12.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。